157 related articles for article (PubMed ID: 35075667)
1. Advances in the role of heat shock protein 90 in prostate cancer.
Fu Z; Jia B
Andrologia; 2022 May; 54(4):e14376. PubMed ID: 35075667
[TBL] [Abstract][Full Text] [Related]
2. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
3. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
4. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.
Ischia J; Saad F; Gleave M
Curr Opin Urol; 2013 May; 23(3):194-200. PubMed ID: 23385973
[TBL] [Abstract][Full Text] [Related]
5. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells.
Eguchi T; Sogawa C; Ono K; Matsumoto M; Tran MT; Okusha Y; Lang BJ; Okamoto K; Calderwood SK
Cells; 2020 Mar; 9(3):. PubMed ID: 32204513
[TBL] [Abstract][Full Text] [Related]
6. Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer.
Albany C; Hahn NM
Asian J Androl; 2014; 16(3):359-63. PubMed ID: 24713836
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
Eskew JD; Sadikot T; Morales P; Duren A; Dunwiddie I; Swink M; Zhang X; Hembruff S; Donnelly A; Rajewski RA; Blagg BS; Manjarrez JR; Matts RL; Holzbeierlein JM; Vielhauer GA
BMC Cancer; 2011 Oct; 11():468. PubMed ID: 22039910
[TBL] [Abstract][Full Text] [Related]
8. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma.
Hoang AT; Huang J; Rudra-Ganguly N; Zheng J; Powell WC; Rabindran SK; Wu C; Roy-Burman P
Am J Pathol; 2000 Mar; 156(3):857-64. PubMed ID: 10702402
[TBL] [Abstract][Full Text] [Related]
9. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
[TBL] [Abstract][Full Text] [Related]
10. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
11. Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.
Chen L; Li J; Farah E; Sarkar S; Ahmad N; Gupta S; Larner J; Liu X
Mol Cancer Ther; 2016 Sep; 15(9):2107-18. PubMed ID: 27390342
[TBL] [Abstract][Full Text] [Related]
12. The heat shock protein 70 inhibitor VER155008 suppresses the expression of HSP27, HOP and HSP90β and the androgen receptor, induces apoptosis, and attenuates prostate cancer cell growth.
Brünnert D; Langer C; Zimmermann L; Bargou RC; Burchardt M; Chatterjee M; Stope MB
J Cell Biochem; 2020 Jan; 121(1):407-417. PubMed ID: 31222811
[TBL] [Abstract][Full Text] [Related]
13. Hsp90: still a viable target in prostate cancer.
Centenera MM; Fitzpatrick AK; Tilley WD; Butler LM
Biochim Biophys Acta; 2013 Apr; 1835(2):211-8. PubMed ID: 23287571
[TBL] [Abstract][Full Text] [Related]
14. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
Rice MA; Kumar V; Tailor D; Garcia-Marques FJ; Hsu EC; Liu S; Bermudez A; Kanchustambham V; Shankar V; Inde Z; Alabi BR; Muruganantham A; Shen M; Pandrala M; Nolley R; Aslan M; Ghoochani A; Agarwal A; Buckup M; Kumar M; Going CC; Peehl DM; Dixon SJ; Zare RN; Brooks JD; Pitteri SJ; Malhotra SV; Stoyanova T
Cell Rep Med; 2022 Feb; 3(2):100502. PubMed ID: 35243415
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer.
Altieri DC
Future Oncol; 2010 Apr; 6(4):487-9. PubMed ID: 20373861
[No Abstract] [Full Text] [Related]
16. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
[TBL] [Abstract][Full Text] [Related]
17. Cell surface heat shock protein 90 modulates prostate cancer cell adhesion and invasion through the integrin-β1/focal adhesion kinase/c-Src signaling pathway.
Liu X; Yan Z; Huang L; Guo M; Zhang Z; Guo C
Oncol Rep; 2011 May; 25(5):1343-51. PubMed ID: 21369706
[TBL] [Abstract][Full Text] [Related]
18. The co-chaperone p23 promotes prostate cancer motility and metastasis.
Cano LQ; Lavery DN; Sin S; Spanjaard E; Brooke GN; Tilman JD; Abroaf A; Gaughan L; Robson CN; Heer R; Mauri F; de Rooij J; Driouch K; Bevan CL
Mol Oncol; 2015 Jan; 9(1):295-308. PubMed ID: 25241147
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
[TBL] [Abstract][Full Text] [Related]
20. Targeting heat shock protein 90 for anti-cancer drug development.
Aswad A; Liu T
Adv Cancer Res; 2021; 152():179-204. PubMed ID: 34353437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]